Investigators at Northwestern Medicine have developed a combination therapy to enhance MYC inhibitor efficacy for aggressive cancers. MYC is a key driver of tumor growth and resistance in many cancers. The study utilized a genome-wide CRISPR screen in MYC-dependent prostate cancer cells treated with a novel MYC inhibitor called MYCi975. The research aimed to identify patient subgroups most likely to benefit from treatment and explore which other drugs could be combined for better results. Specific gene deletions increased sensitivity to the MYC inhibitor, indicating potential for improved treatment outcomes.
The MYC oncogene drives tumor growth and resistance in over half of human cancers. MYC inhibitors like MYCi975 show promise in pre-clinical trials.
Abdulkadir's team used a genome-wide CRISPR screen to identify gene targets that enhance MYC inhibitor efficacy, aiming to optimize patient treatment.
The study revealed that deleting specific genes could increase sensitivity to MYCi975, potentially leading to better treatment responses in certain patients.
One unexpected finding was the disruption of a particular class of genes related to mitochondrial function, suggesting a novel avenue for enhancing MYC treatment.
Collection
[
|
...
]